Akanda Corp., an international medical cannabis company listed on Nasdaq (AKAN) and which owns the Portuguese company Holigen, announced this week the signing of a non-binding letter of intent (LOI) with SOMAÍ Pharmaceuticals, for the sale of its subsidiary RPK Biopharma, based in Sintra. Michael Sassano, CEO of SOMAÍ Pharmaceuticals, confirmed to CannaReporter that the amount paid will be 2 million dollars (1.84 million euros), with the assumption of financial liabilities of approximately 4 million in debt from RPK Biopharma. The end result of this operation will be “one of the few vertical cannabis companies in the EU", assures Sassano. You can listen to or read this article by Laura Ramos in Portuguese, English, German, French, Italian, Spanish, Dutch, Hebrew, Thai, Japanese, Arabic, Hindi or Mandarin at CannaReporter.eu RE-SHARE POST CREDIT: CANNAREPORTER

Posted by Richie Bragado at 2024-02-03 01:00:34 UTC